Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$136.21 +0.1%	$132.94	$99.71 ▼ $141.23	$236.99B	0.73	6.14 million shs	5.26 million shs
MRK Merck & Co., Inc.	$81.75 +3.3%	$79.09	$73.31 ▼ $129.93	$205.28B	0.38	13.19 million shs	21.28 million shs
NVO Novo Nordisk A/S	$69.85 +1.2%	$69.32	$57.00 ▼ $145.99	$311.88B	0.66	7.24 million shs	6.81 million shs
NVS Novartis	$123.06 +1.7%	$114.16	$96.06 ▼ $123.80	$259.95B	0.59	1.58 million shs	1.39 million shs
PFE Pfizer	$25.03 +3.3%	$23.51	$20.92 ▼ $31.54	$142.30B	0.57	41.45 million shs	56.82 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	+1.26%	+2.12%	+1.80%	+3.33%	+30.97%
MRK Merck & Co., Inc.	+0.33%	-1.20%	+3.03%	-9.06%	-36.03%
NVO Novo Nordisk A/S	+0.82%	-1.07%	-3.28%	+1.56%	-51.62%
NVS Novartis	+0.65%	+2.99%	+4.68%	+10.58%	+13.73%
PFE Pfizer	+0.31%	+0.96%	+3.45%	-1.04%	-13.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABT Abbott Laboratories	4.8971 of 5 stars	2.4	3.0	4.2	4.5	2.9	2.5	2.5
MRK Merck & Co., Inc.	4.9963 of 5 stars	3.2	3.0	5.0	3.9	3.0	2.5	3.8
NVO Novo Nordisk A/S	4.6656 of 5 stars	4.1	5.0	2.5	0.0	2.0	0.0	3.1
NVS Novartis	1.6441 of 5 stars	1.0	3.0	2.5	0.0	2.8	0.0	1.9
PFE Pfizer	4.8773 of 5 stars	2.3	3.0	4.2	4.3	2.8	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABT Abbott Laboratories	2.76	Moderate Buy	$142.61	4.70% Upside
MRK Merck & Co., Inc.	2.43	Hold	$109.19	33.56% Upside
NVO Novo Nordisk A/S	2.27	Hold	$112.00	60.34% Upside
NVS Novartis	2.00	Hold	$123.38	0.26% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	16.53% Upside

Current Analyst Ratings Breakdown

Latest PFE, NVS, MRK, NVO, and ABT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	ABT Abbott Laboratories	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	ABT Abbott Laboratories	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$143.00
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00
4/30/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $25.00
4/28/2025	NVO Novo Nordisk A/S	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/25/2025	NVO Novo Nordisk A/S	Dbs Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sell
4/22/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$85.00
4/22/2025	PFE Pfizer	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Neutral	$24.00
4/17/2025	ABT Abbott Laboratories	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$133.00 ➝ $145.00
4/17/2025	ABT Abbott Laboratories	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$132.00 ➝ $142.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABT Abbott Laboratories	$41.95B	5.65	$6.67 per share	20.41	$27.62 per share	4.93
MRK Merck & Co., Inc.	$64.17B	3.20	$9.78 per share	8.36	$18.33 per share	4.46
NVO Novo Nordisk A/S	$42.12B	7.40	$3.98 per share	17.56	$4.66 per share	14.99
NVS Novartis	$50.32B	5.17	$10.97 per share	11.22	$21.59 per share	5.70
PFE Pfizer	$63.63B	2.24	$4.52 per share	5.54	$15.62 per share	1.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABT Abbott Laboratories	$13.40B	$7.71	17.67	23.77	2.55	31.89%	19.01%	10.82%	7/17/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	11.90	8.26	0.82	27.27%	43.23%	17.11%	7/29/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.38	20.67	14.99	1.22	34.52%	80.94%	24.23%	8/6/2025 (Estimated)
NVS Novartis	$11.94B	$6.40	19.23	13.97	1.73	24.70%	39.44%	16.43%	7/17/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	18.14	8.26	0.88	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest PFE, NVS, MRK, NVO, and ABT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	N/A	N/A	N/A	$15.92 billion	N/A
7/17/2025	Q2 2025	ABT Abbott Laboratories	$1.25	N/A	N/A	N/A	$11.01 billion	N/A
7/17/2025	Q2 2025	NVS Novartis	$2.37	N/A	N/A	N/A	$13.94 billion	N/A
5/7/2025	Q1 2025	NVO Novo Nordisk A/S	$0.92	$0.92	N/A	$0.92	N/A	$11.87 billion
4/29/2025	Q1 2025	NVS Novartis	$2.12	$2.28	+$0.16	$1.83	$12.92 billion	$13.23 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion
4/16/2025	Q1 2025	ABT Abbott Laboratories	$1.07	$1.09	+$0.02	$0.76	$10.38 billion	$10.36 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABT Abbott Laboratories	$2.36	1.73%	N/A	30.61%	54 Years
MRK Merck & Co., Inc.	$3.24	3.96%	N/A	47.16%	14 Years
NVO Novo Nordisk A/S	$1.64	2.35%	N/A	48.52%	N/A
NVS Novartis	$2.60	2.11%	N/A	40.63%	N/A
PFE Pfizer	$1.72	6.87%	N/A	124.64%	16 Years

Latest PFE, NVS, MRK, NVO, and ABT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
6/13/2025	ABT Abbott Laboratories	quarterly	$0.59	1.73%	7/15/2025	7/15/2025	8/15/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABT Abbott Laboratories	0.26	1.78	1.27
MRK Merck & Co., Inc.	0.69	1.41	1.16
NVO Novo Nordisk A/S	0.70	0.74	0.56
NVS Novartis	0.56	0.79	0.61
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABT Abbott Laboratories	75.18%
MRK Merck & Co., Inc.	76.07%
NVO Novo Nordisk A/S	11.54%
NVS Novartis	13.12%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABT Abbott Laboratories	0.46%
MRK Merck & Co., Inc.	0.09%
NVO Novo Nordisk A/S	0.07%
NVS Novartis	0.01%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABT Abbott Laboratories	114,000	1.74 billion	1.73 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable
NVO Novo Nordisk A/S	77,349	4.47 billion	4.46 billion	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

PFE, NVS, MRK, NVO, and ABT Headlines

Recent News About These Companies

Pfizer (NYSE:PFE) Trading 3.3% Higher - What's Next?

1 hour ago | marketbeat.com

Pfizer ends phase 2 trial for lymphoma drug from Trillium acquisition

2 hours ago | seekingalpha.com

Cannabis Lighting Market Report 2025-2030 | Share Analysis, Industry Trends & Statistics, Growth Forecasts - Pfizer Ventures into Cannabis with $6.7 Billion Deal, Boosting Industry Growth

July 1 at 11:06 AM | globenewswire.com

Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth

July 1 at 10:36 AM | zacks.com

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

July 1 at 10:01 AM | zacks.com

Sumitomo Mitsui DS Asset Management Company Ltd Has $19.82 Million Holdings in Pfizer Inc. (NYSE:PFE)

July 1 at 8:38 AM | marketbeat.com

BLB&B Advisors LLC Sells 25,375 Shares of Pfizer Inc. (NYSE:PFE)

July 1 at 8:09 AM | marketbeat.com

Alta Advisers Ltd Buys 13,100 Shares of Pfizer Inc. (NYSE:PFE)

July 1 at 7:05 AM | marketbeat.com

Hixon Zuercher LLC Acquires 14,753 Shares of Pfizer Inc. (NYSE:PFE)

July 1 at 6:47 AM | marketbeat.com

326,865 Shares in Pfizer Inc. (NYSE:PFE) Purchased by CHURCHILL MANAGEMENT Corp

July 1 at 6:30 AM | marketbeat.com

Pfizer (NYSE:PFE) Expands Collaboration With XtalPi To Enhance Drug Discovery Platform

July 1 at 4:42 AM | finance.yahoo.com

US House committee subpoenas former Pfizer executive over alleged COVID vaccine delay

June 30 at 4:52 PM | investing.com

House committee subpoenas Pfizer executive in probe of alleged COVID vaccine delay, CNN reports

June 30 at 4:01 PM | reuters.com

Pfizer’s Promising Phase 3 Study on Prostate Cancer Treatment: A Potential Game Changer

June 30 at 12:15 PM | tipranks.com

Pfizer’s Sayana Press Study: Optimizing Drug Delivery for Better Outcomes

June 30 at 12:15 PM | tipranks.com

Essex LLC Cuts Stock Holdings in Pfizer Inc. (NYSE:PFE)

June 30 at 9:04 AM | marketbeat.com

First Fiduciary Investment Counsel Inc. Buys 40,783 Shares of Pfizer Inc. (NYSE:PFE)

June 30 at 8:40 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Acquired by Argent Advisors Inc.

June 30 at 7:58 AM | marketbeat.com

New York State Teachers Retirement System Sells 142,670 Shares of Pfizer Inc. (NYSE:PFE)

June 30 at 6:41 AM | marketbeat.com

Amalgamated Bank Purchases 16,085 Shares of Pfizer Inc. (NYSE:PFE)

June 30 at 6:22 AM | marketbeat.com

Verity Asset Management Inc. Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)

June 30 at 6:21 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
RKLB Breakout Fails Near Highs: Should Investors Be Concerned?
By Ryan Hasson | June 11, 2025
View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
By Leo Miller | June 7, 2025
View With Novo Nordisk's CEO Out, Wall Street Wants an American Leader

PFE, NVS, MRK, ABT, and NVO Company Descriptions

Abbott Laboratories NYSE:ABT

$136.21 +0.20 (+0.15%)

Closing price 03:59 PM Eastern

Extended Trading

$135.54 -0.68 (-0.50%)

As of 04:20 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Merck & Co., Inc. NYSE:MRK

$81.75 +2.59 (+3.27%)

Closing price 03:59 PM Eastern

Extended Trading

$82.08 +0.33 (+0.40%)

As of 04:28 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novo Nordisk A/S NYSE:NVO

$69.85 +0.83 (+1.20%)

Closing price 03:59 PM Eastern

Extended Trading

$69.94 +0.09 (+0.13%)

As of 04:28 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novartis NYSE:NVS

$123.06 +2.05 (+1.69%)

Closing price 03:59 PM Eastern

Extended Trading

$123.11 +0.05 (+0.04%)

As of 04:28 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Pfizer NYSE:PFE

$25.03 +0.79 (+3.26%)

Closing price 03:59 PM Eastern

Extended Trading

$25.05 +0.02 (+0.10%)

As of 04:29 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PFE, NVS, MRK, NVO, and ABT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PFE, NVS, MRK, NVO, and ABT Earnings

Compare Dividends

Latest PFE, NVS, MRK, NVO, and ABT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PFE, NVS, MRK, NVO, and ABT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PFE, NVS, MRK, ABT, and NVO Company Descriptions

Abbott Laboratories NYSE:ABT

Merck & Co., Inc. NYSE:MRK

Novo Nordisk A/S NYSE:NVO

Novartis NYSE:NVS

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools